Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival, Pancreatic Cancer Trial Results In 2020-2021.
TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival, Pancreatic Cancer Trial Results In 2020-2021
